• Diagnosis of CD22-expressing blood cancer that has relapsed or is refractory after at least 2 lines of standard therapy including CD19-directed treatment
• Disease relapse after standard relapse protocol including CD19 CAR T-cell therapy
• Primary refractory disease after 2 induction chemotherapy lines
• Age between 1 and 80 years
• CD22 expression on at least 70% of cancer cells confirmed by flow cytometry
• Adequate CD3+ T-cell count above 120 cells per microliter of blood
• Clinical performance status: Karnofsky score of 50% or higher for patients older than 10 years
• Clinical performance status: Lansky score of 50% or higher for patients 10 years or younger
• Negative pregnancy test for females of child-bearing potential
• Normal cardiac function with left ventricular ejection fraction over 45% or shortening fraction over 28%
• At least 60 days since autologous or allogeneic bone marrow transplant
• At least 30 days since prior CAR therapy if no response

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety